Höland, Katrin; Boller, Danielle; Hagel, Christian; Dolski, Silvia; Treszl, András; Pardo, Olivier E.; Cwiek, Paulina; Salm, Fabiana; Leni, Zaira; Shepherd, Peter R; Styp-Rekowska, Beata; Djonov, Valentin; von Bueren, André O.; Frei, Karl; Arcaro, Alexandre (2014). Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS ONE, 9(4), e94132. Public Library of Science 10.1371/journal.pone.0094132
|
Text
Paper 3 Höland.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (9MB) | Preview |
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in human cancer and plays a crucial role in glioblastoma biology. We were interested in gaining further insight into the potential of targeting PI3K isoforms as a novel anti-tumor approach in glioblastoma. Consistent expression of the PI3K catalytic isoform PI3K p110α was detected in a panel of glioblastoma patient samples. In contrast, PI3K p110β expression was only rarely detected in glioblastoma patient samples. The expression of a module comprising the epidermal growth factor receptor (EGFR)/PI3K p110α/phosphorylated ribosomal S6 protein (p-S6) was correlated with shorter patient survival. Inhibition of PI3K p110α activity impaired the anchorage-dependent growth of glioblastoma cells and induced tumor regression in vivo. Inhibition of PI3K p110α or PI3K p110β also led to impaired anchorage-independent growth, a decreased migratory capacity of glioblastoma cells, and reduced the activation of the Akt/mTOR pathway. These effects were selective, because targeting of PI3K p110δ did not result in a comparable impairment of glioblastoma tumorigenic properties. Together, our data reveal that drugs targeting PI3K p110α can reduce growth in a subset of glioblastoma tumors characterized by the expression of EGFR/PI3K p110α/p-S6.
Actions (login required)
 |
Edit item |